Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Sanofi Exploring Acquisition of KRAS Cancer Drugmaker Mirati

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Oct 10, 2023 7:09am

178 Views

Post# 35676559

RE:RE:RE:RE:RE:RE:RE:Sanofi Exploring Acquisition of KRAS Cancer Drugmaker Mirati

Thank you Canadafan for your thoughts and speculations. It's the best we can do for now without new results from panc or other studies. I prefer that by far than repeating like a parrot the same posts week after week. Hopefully I have the parrot on ignore! GLTA

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project